Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| CELLULAR TECHNICAL SERVICES CO INC | 8,335,819 | reported | 21 Apr 2014 | tx 3+13,439,531−1,240,176.4 |
| ADMA BIOLOGICS, INC. | 3,620,143 | reported | 22 Oct 2013 | tx 1+411,765 |
| Durata Therapeutics, Inc. | 3,030,175 | reported | 21 Mar 2014 | tx 2−100,649 |
| T2 Biosystems, Inc. | 2,068,755 | reported | 12 Aug 2014 | tx 4+2,523,300−3,516,884 |
| Loxo Oncology, Inc. | 2,038,920 | reported | 10 Jul 2018 | tx 1−1,400,000 |
| Elevation Oncology, Inc. | 31,238 | reported | 16 Jun 2023 | tx 3+78,095 |
| Monte Rosa Therapeutics, Inc. | 30,700 | reported | 13 Jun 2025 | tx 5+135,432 |
| AGILE THERAPEUTICS INC | 14,000 | reported | 10 Jun 2015 | tx 3+1,368,333 |
| INTERPHARM HOLDINGS INC | 10,412 | reported | 12 Dec 2008 | tx 6+872,240−10,001 |
| Aclaris Therapeutics, Inc. | 0 | reported | 06 Jun 2025 | tx 40+329,581−253,090 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 13 Jun 2025 | GRANT_AWARD | Monte Rosa Therapeutics, Inc. | 30,700 | 0.00 USD | deriv |
| 06 Jun 2025 | EXERCISE | Aclaris Therapeutics, Inc. | 4,793 | — | |
| 05 Jun 2025 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 42,350 | 0.00 USD | deriv |
| 06 Jun 2025 | EXERCISE | Aclaris Therapeutics, Inc. | 4,793 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 11,580 | 0.00 USD | deriv |
| 12 Jun 2024 | GRANT_AWARD | Monte Rosa Therapeutics, Inc. | 22,100 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 15,750 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 4,793 | 0.00 USD | deriv |
| 01 Jun 2024 | EXERCISE | Aclaris Therapeutics, Inc. | 4,660 | — | |
| 01 Jun 2024 | EXERCISE | Aclaris Therapeutics, Inc. | 4,660 | 0.00 USD | deriv |
| 16 Jun 2023 | GRANT_AWARD | Elevation Oncology, Inc. | 31,238 | 0.00 USD | deriv |
| 14 Jun 2023 | GRANT_AWARD | Monte Rosa Therapeutics, Inc. | 20,500 | 0.00 USD | deriv |
| 02 Jun 2023 | EXERCISE | Aclaris Therapeutics, Inc. | 4,507 | — | |
| 01 Jun 2023 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 4,660 | 0.00 USD | deriv |
| 01 Jun 2023 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 15,750 | 0.00 USD | deriv |
| 02 Jun 2023 | EXERCISE | Aclaris Therapeutics, Inc. | 4,507 | 0.00 USD | deriv |
| 11 Nov 2022 | SALE | Aclaris Therapeutics, Inc. | 41,160 | 17.06 USD | |
| 10 Nov 2022 | SALE | Aclaris Therapeutics, Inc. | 11,395 | 17.02 USD | |
| 14 Nov 2022 | SALE | Aclaris Therapeutics, Inc. | 1,371 | 17.08 USD | |
| 24 Oct 2022 | SALE | Aclaris Therapeutics, Inc. | 14,616 | 17.01 USD | |
| 26 Oct 2022 | SALE | Aclaris Therapeutics, Inc. | 14,540 | 17.01 USD | |
| 25 Oct 2022 | SALE | Aclaris Therapeutics, Inc. | 12,018 | 17.02 USD | |
| 18 Oct 2022 | SALE | Aclaris Therapeutics, Inc. | 32,093 | 16.89 USD | |
| 17 Oct 2022 | SALE | Aclaris Therapeutics, Inc. | 19,944 | 16.05 USD | |
| 07 Oct 2022 | SALE | Aclaris Therapeutics, Inc. | 7,324 | 16.16 USD |
1 purchase reported after at least 12 months of silence — most recent on 16 Aug 2017.